EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Michael Chiorean  1     Severine Vermeire  2     Julian Panés  3     Laurent Peyrin-Biroulet  4     Jinkun Zhang  5     Bruce E. Sands  6     Chris Cabell     Snehal U. Naik     William Sandborn    
1 Virginia Mason Medical Center,Seattle,United States
2 University Hospital Leuven,Leuven,Belgium
3 Hospital Clinic de Barcelona, IDIBAPS, CIBERehd,Barcelona,Spain
4 INSERM U 954, Lorraine University,Vandoeuvre-lès-Nancy,France
5 Arena Pharmaceuticals,San Diego,United States
6 Icahn School of Medicine at Mount Sinai,New York,United States

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing